Infex Therapeutics is a leading anti-infectives specialist, with a broad and diverse pipeline of innovative best-in-class and first-in-class drug candidates to address the urgent global shortage of novel anti-infective treatments.

The Company is building a differentiated pipeline through in-house drug discovery, acquisition, co-development and in-licensing of early stage/pre-clinical candidates, developing them to clinical proof of concept before licensing to commercial pharma partners

Investor Alerts